Granulocyte colony stimulating factor (G-CSF), one of the family of hemopoietic regulators (Nicola, 1990 ) is able to stimulate proliferation of neutrophil progenitor cells in vitro (Metcalf & Nicola, 1983) . The characterisation (Nicola et al., 1979) and molecular cloning of this molecule (Nagata et al., 1986) has allowed its evaluation in a variety of clinical settings including for example, administration of G-CSF to patients following high dose chemotherapy and bone marrow transplantation (Sheridan et al., 1989) .
In addition, studies of both G-CSF (Duhrsen et al., 1988; Gabrilove et al., 1988) and GM-CSF (Socinski et al., 1988; Villeval et al., 1990) have shown an unexpected ability of these growth factors to mobilise progenitor cells into the peripheral blood, leading to a 100-fold increase in total numbers being observed after G-CSF administration. In contrast, Multi-CSF (or IL-3) appears to induce only a 2-fold increase in PBPC (Ottoman et al., 1990) .
Autologous bone marrow transplantation is being increasingly used to allow administration of high dose chemotherapy for the treatment of various malignancies. Following high dose chemotherapy, there is a period of pancytopenia during which patients are at risk from infection and haemorrhage until the infused marrow cells repopulate the peripheral blood with mature progeny. In an attempt to circumvent some of these problems, peripheral blood progenitor cells (PBPC) have been used to accelerate hemopoietic regeneration. Several groups have reported that PBPC can be mobilised by chemotherapy, collected cryopreserved and used subsequently to rescue patients following high dose chemotherapy Richman et al., 1976) . The use of PBPC collected under normal basal conditions has limited application because of the very low levels of progenitor cells found under conditions of steady-state hemopoiesis (Stiff et al., 1986; Barr & McBride, 1982) .
The present study focuses on analysing the characteristics of PBPC collected by leukapheresis following administration of G-CSF alone.
Materials and methods
Criteria for eligibility and description ofpatients Two groups of patients were eligible to receive G-CSF in this study. One group involved patients with non-myeloid malignancies who were in remission after initial chemotherapy but had poor prognostic features (acute lymphoblastic leukaemia and non-Hodgkin's lymphoma). The other group of patients were those with an inadequate response to, or in relapse after prior chemotherapy (acute lymphoblastic leukaemia, nonHodgkin's lymphoma, Hodgkin's disease and germ cell tumour) (Table I ). This study was undertaken at the Royal Properties of G-CSF Recombinant human Granulocyte Colony-Stimulating Factor (G-CSF) (Amgen Corp., Thousand Oaks, CA) has a molecular weight of 18,800 daltons. It differs from the native protein in that the N-terminal amino acid is a methionine and the protein is not 0-glycosylated. The G-CSF protein was produced in Escherichia coli and purified using a series of chromatographic steps. The final product was formulated in an aqueous buffer as a sterile solution and shown to be biologically active and free of pyrogens.
Collection protocolfor PBPC
Prior to G-CSF treatment leukapheresis was performed to determine baseline levels of PBPC. Patients then received 12 fig kg-' day-' of G-CSF for either 6 or 7 days via continuous subcutaneous infusion through a 23 gauge needle connected to a Comed infusion pump. Leukapheresis was performed on either consecutive days (days 5, 6, and 7; n = 13) or alternate days (days 4, 6 and 8; n = 8) on different patients, using a Fenwal CS-3000 cell separator (Baxter, Deerfield, Illinois) with the red cell interface set at 020 units. Each leukapherisis involved processing a minimum of 7 litres of blood. At the end of processing, an aliquot of collected cells was removed for subsequent progenitor cell assay.
Processing of blood samples Peripheral blood and leukapheresis samples were collected on the days indicated above. Samples were washed and subjected to gradient centrifugation for 20 min, at 400 g using Ficoll-Paque (density 1.077 g ml-1, Pharmacia, Inc., Uppsala, Sweden). The light density interface cells were collected, washed and resuspended in RPMI 1640 with 10% foetal calf serum (FCS). Staining of the interface cells with May-Grunwald -Giemsa indicated that approximately 60% of the cells present in this fraction were lymphocytes, 30-40% were monocytes with low numbers of myeloblasts, promyelocytes, metamyeloblasts and normoblasts. There was no significant difference in cell type distribution at the light density interface before and after G-CSF treatment. After Ficoll separation, cells in the pellet were >95% mature neutrophils with the remainder of cells being band forms.
Progenitor cell assay Progenitor cells were grown in agar culture prepared by adding 1 vol of double strength Iscove's modified Dulbecco's medium (IMDM) and 1 vol of FCS to 2 vol of 0.6% agar in a final volume of 1 ml (Metclalf, 1984) . Cultures were stimulated by 500 units of purified recombinant human G-CSF (Amgen, CA, USA specific activity, -1IO U mg-') dissolved in 0.1 ml of saline and 1,500 units of purified recombinant human GM-CSF (Schering-Plough, specific activity, 5 x 108 U mg-'). Additional cultures were stimulated with recombinant human erythropoietin (EPO: a gift from Dr A. Burgess -Ludwig Institute for Cancer Research, Melbourne and titrated to be a maximal stimulus at a dilution of 1:100 or purchased from Cilag AG, International, Switzerland and used a 5 U ml-') plus 100 ,sl of pre-titrated human placental conditioned medium (HPCM). Cells from peripheral blood leukapheresis were cultured both at 2 x 105 and 4 x 105 cells/ dish. In control experiments adherence depletion techniques did not result in an increase in the number of colonies generated. Cultures were incubated in a humidified atmosphere of 5% CO2 in air at 37°C for 14 days. Replicate cultures were scored after 14 days using a dissection microscope at 35 x magnification. Clones of more than 40 cells were scored as colonies. Pre-CFC assay To detect the presence of an earlier hemopoietic cell population (pre-CFC's), light density mononuclear cells were collected from the leukapheresis product and a pre-CFC assay performed as previously described (Moore et al., 1980) . Briefly, adherence depletion prior to liquid culture was performed by incubating not more than 0.4 x 106 cells cm-2 in a culture flask (Nunclon, Denmark) for 1 h, at 37°C in a humidified incubator with 10% CO2 in air. Non-adherent cells were removed and 1 x 106 cells ml-' were cultured for 7 days in RPMI plus 10% FCS which also contained an optimal HPCM concentration. After the liquid culture phase, cells were collected, washed and resuspended in 500 LI RPMI plus 10% FCS. An aliquot was then cultured in agar together with GM-CSF (1,500 U ml1'), HPCM (100 glI ml-') and EPO (5 U ml-', Cilag). Colonies were scored on day 14.
In some experiments no initial adherence depletion was performed, and the mononuclear cells were cultured for 7 days as described.
For all samples a colony assay was performed prior to the liquid culture phase to quantitate number of input colony forming cells (CFC's).
Staining of cultures
Whole plate staining was performed by fixing agar cultures with 2.5% glutaraldehyde and floating them onto glass slides. Plates were air dried and stained with Luxol fast blue and haematoxylin (Metcalf, 1984) .
Results

Efficient collection of G-CSF mobilised PBPC
Initial experiments were performed to examine the efficiency of collection of G-CSF mobilised PBPC using a leukapheresis technique. This was determined by enumerating PBPC detectable both in peripheral blood and in blood returning to the patient at the end of the leukapheresis collection (return line sample). Table II shows that the leukapheresis collection procedure was extremely efficient both prior to G-CSF and after G-CSF treatment. For patients with a normal white cell count and normal levels of circulating PBPC, leukapheresis collection was very efficient with no PBPC detected in the return line sample. Similarly, for patients wth markedly elevated white cell counts and >3000 Granulocyte-Macrophage (GM)-CFC per ml the leukapheresis procedure extracted essentially all PBPC as none were detected in blood samples from the return line.
Because density separation using a Ficoll gradient is frequently used clinically to concentrate the leukapheresis product, we examined the distribution of G-CSF mobilised PBPC after separation on a Ficoll gradient. The data presented in Table III shows that prior to G-CSF, virtually 100% of PBPC in the leukapheresis product were of light density (<1.077 g ml-') and were collected at the interface layer. Similarly, after G-CSF treatment even though numbers of PBPC were markedly increased, 98% were of light density and recovered at the interface layer. Thus, Ficoll gradient separation served as a rapid and efficient method enriching for the vast majority of G-CSF mobilised PBPC.
Elevated progenitor cell levels after G-CSF treatment The white cell count (WCC) and progenitor cell levels were determined in peripheral blood and leukapheresis samples of patients before treatment with G-CSF and then on either days 4, 6 and 8 or days 5, 6, and 7 after administration of (mean increase of 6-fold) (Figure 1 ). This level was maintained with continued treatment of G-CSF. As expected, progenitor cell assays performed on peripheral blood samples showed low levels of PBPC (39 ± 15 GM-CFC ml-' blood) before G-CSF treatment. Although there was considerable heterogeneity in response, maximum levels of PBPC were observed after 5 days of G-CSF administration. As previously reported (Diihrsen et al., 1988) increases were observed in all cell lineages (see below). GM-CFC were increased up to 3000-fold (median increase in 76-fold) ( Figure 1 ). As shown in Figure 1 , increases of up to 3000-fold (median increase of 38-fold) were also observed for day 14 erythroid progenitors. Thus, although there was a median increase in the peripheral WCC of approximately 8-fold during G-CSF treatment, there was a disproportionate increase of approximately 40-80-fold in levels of PBPC.
Total mononuclear cell counts and progenitor cell levels were also analysed in the leukapheresis product (Figure 2) . Consistent with the observed increase in blood WCC following treatment with G-CSF, a 5-fold median increase was seen in total mononuclear cells collected by leukapheresis. In contrast there was an increase in GM-CFC of up to 5300-fold above baseline (median increase of 62-fold) and in erythroid progenitors of up to 8000-fold (median increase of 47-fold) (Figure 2 ). Similar increases were also observed in eosinophil progenitor and multipotential progenitor cells in the leukapheresis samples (Table IV) . Thus, the changes observed in the leukapheresis product were in keeping with those seen in the peripheral blood, with median increases of 50-60-fold in progenitor cell levels compared with a median increase of only 5-fold in total cell counts.
Comparison of collection schedules Comparison of samples from patients undergoing leukapheresis on days 5, 6 and 7 with days 4, 6 and 8 showed no significant differences in the total number of mononuclear cells harvested. However there were significant differences in the number of PBPC collected on different days. Figure 3 shows the number of GM-CFC collected from patients on days 4-8. Maximum numbers of GM-CFC were collected on day 5 and fewer progenitor cells were harvested after that time. Between 2-3-fold fewer GM-CFC were collected on days 4 (P<0.02), 7 (P<0.03) and 8 (P<0.04) (Student ttest). Similar results were obtained for erythroid, eosinophil and multipotential progenitor cells (data not shown). The number of progenitor cells collected by the two collection schedules (days 4, 6, 8 vs days 5, 6, 7) was also compared (Figure 3) . It was of interest to note that there was no difference in the number of GM-CFC harvested at day 6 using the two collection protocols. Therefore the decline in number of progenitor cells seen with the day 5, 6, 7 collection schedule may reflect a true biological response to G-CSF rather than simply being a consequence of collections on consecutive days. Conversely the day 4, 6, 8 schedule was not associated with heightened levels of progenitor cells that might have been predicted given the 'rest' day between collections. The total number of GM-CFC harvested using these two schedules was also compared. Harvesting on days 4, 6, 8 produced a total of 1.2± 0.47 x 107 GM-CFC compared with 2.02 ± 0.37 x 107 GM-CFC on days 5, 6, 7. Although because of patient to patient heterogeneity the total number of GM-CFC collected on days 4, 6, 8 was not statistically different from the total number collected on days 5, 6, 7 (P<0.2), seven of the 13 patients on the consecutive day collection schedule achieved levels of GM-CFC kg-' greater than the number required for reconstitution (i.e. 30 x 104 GM-CFC kg-') . In contrast only one of the eight patients on the alternate day collection protocol had greater than 30 x 104 GM-CFC kg-'. This suggests that the preferred schedule for harvesting maximal number of G-CSF mobilised PBPC was days 5, 6, 7.
Mobilisation of PBPC after two cycles G-CSF
In an attempt to maximise PBPC collected by leukapheresis, two patients received two cycles of G-CSF with 10 weeks (Patient 1) or 5 weeks (Patient 2) between cycles. The WCC and number of GM-CFC collected are presented in Table V . For patient 1 there was a poor response to G-CSF in the first cycle with only a 4-fold increase observed in the WCC. A similar low level response was observed after administration of the second cycle of G-CSF. Low levels of GM-CFC were observed in the leukapheresis product after both the first (7.2 x 104 GM-CFC kg-') and second (6.4 x 104 GM-CFC kg-') cycle of G-CSF. For patient 2, G-CSF increased the WCC by approximately 9-fold and a similar effect was observed with the second cycle of G-CSF therapy. As with patient 1, there was no difference in GM-CFC levels obtained in the leukapheresis product after 1 or 2 cycles of G-CSF. Thus, a prior cycle of G-CSF did not appear to influence subsequent mobilisation of PBPC eithuer positively or negatively and a poor response to the first cycle predicted a poor response to the second cycle of G-CSF.
G-CSF mobilises Pre-CFC
To determine whether an early population of progenitor cells ('pre-CFC') was mobilised by G-CSF and could be detected in the leukapheresis product, mononuclear cells were cultured in liquid for 7 days then CFC's quantified using a clonal assay as previously described (Moore et al., 1980) . The number of CFC generated during the liquid culture phase was compared to the number of input CFC. In the experiments shown in Figure 4 , the number of CFC generated was up to 60-fold greater than input CFC. Because greater numbers of CFC were frequently generated after liquid culture compared to the number of input colonies it seemed unlikely that colonies generated after liquid culture simply reflected survival of input progenitor cells. However, as was the case with the progenitor cell levels, the pre-CFC data also showed considerable variation from patient to patient. This is partly illustrated in Figure 4 where one can see the variability in the ratio of input to output colony numbers. Accordingly as a result of treatment with G-CSF, there was an increase in levels of pre-CFC ranging between 15-50-fold above baseline values. above baseline was observed on day 5 compared with a 30-fold mean increase in GM-CFC. A similar increase in pre-CFC's was evident on day 6 with a mean increase of 6-fold on day 7. It was interesting to note the apparent dissociation between the fold increase in GM-CFC compared with pre-CFC on day 5 possibly reflecting differences in the kinetics of release in response to G-CSF. These results gave further support for the view that the pre-CFC assay and GM-CFC assay were assessing different populations of cells. This data therefore suggests that G-CSF was able to mobilise earlier populations of cells (pre-CFC) that were also successfully collected by leukapheresis.
Discussion
This study demonstrated that G-CSF can be used to successfully mobilise progenitor and pre-CFC populations into the blood even in a population of patients heavily pretreated with chemotherapy (Table I) . These PBPC were then harvested efficiently using a Fenwal CS-3000 cell separator. The fact that PBPC were efficiently collected using the same machine parameters both before and after G-CSF treatment suggested that the G-CSF mobilised cells shared similar physical properties to PBPC in the resting state. In both situations no CFC were detected in blood returning to the patient. The resting and G-CSF mobilised PBPC also showed similar density characteristics as assessed by behaviour on a Ficoll gradient. As indicatd in Table III Figure  1 ), eosinophil-CFC and multi-CFC (Table IV) . This action of G-CSF was not predicted from the known action of G-CSF in vitro and is supported by other studies that also demonstrated an increase in megakaryocyte and eosinophil CFC's at G-CSF concentrations as low as 3 tLg kg-' day-' (Diihrsen et al., 1988 (Ulich et al., 1991; Andrews et al., 1991) have been used to study the effect of the recently described kit-ligand or stem cell factor (SCF) in vivo (Zsebo et al., 1990) . The action of SCF in humans either alone or in combination, however, remains to be determined.
We were also interested in determining whether G-CSF was able to mnobilise pre-CFC into the peripheral blood. Murine studies (Nicola & Johnson, 1982) have shown that a population of pre-CFC could be assayed by culturing fractionated fetal liver cells in liquid culture over 7 days in a crude mixture of factors (pokeweed mitogen-stimulated spleen cell-conditioned medium). Similar studies used human bone marrow cells grown in liquid culture in HPCM to assay a population of pre-CFC (Moore et al., 1980) which could then be maintained in long-term culture in the presence of an adherent layer. In this study we also used this technique to assay pre-CFC. In this assay, the number of CFC generated was consistently greater than input CFC, implying that CFC were being generated during the liquid culture phase. In studies using murine fetal liver cells (Nicola & Johnson, 1982) , the CFC population died within 5 days while the pre-CFC population reached a maximum at this time. Similar results have been shown for human CFC where the number of GM-CFC fell after 4 days in suspension culture (Jacobsen et al., 1979) . It seems likely then that in addition to its effect on mobilising CFC of all lineages G-CSF was also able to mobilise a population of pre-CFC. The increase in this earlier cell population was only up to 50-fold (compared with increases of up to 3000-fold for GM-CFC) and with kinetics suggesting that these cells might be mobilised somewhat later than CFC.
Other studies have utilised cytotoxic drugs with or without CSF's to mobilise PBPC (Gianni et al., 1989; To et al., 1990) . Although useful in some situations, such protocols are associated with the side-effects of chemotherapy, are less applicable in patients who have had recent intensive chemotherapy and require administration of drugs that may be relatively inactive in particular malignancies. The protocol described in this study may be more widely applicable because it is not associated with these problems -the only side effects being mild bone pain during G-CSF administration and thrombocytopenia during leukapheresis (requiring platelet transfusion in two patients of 21) (Sheridan et al., 1992) . In addition the yield of PBPC using chemotherapy techniques (without addition of CSF's) is 10-100-fold less than with G-CSF alone (Gabrilove et al., 1988; To et al., 1984) . However, based on chemotherapy mobilised PBPC a minimum number of 30 x 104 GM-CFC kg-' is estimated to be required for subsequent engraftment using PBPC transfusion alone . When reinfused, chemotherapy mobilised PBPC hasten neutrophil and platelet recovery following high dose chemotherapy. Similar accelerated platelet recovery was observed when the G-CSF mobilised PBPC from this study were reinfused following high dose chemotherapy (Sheridan et al., 1992) .
There was considerable variability in responses to G-CSF.
This most probably reflects the heterogeneity in this heavily pre-treated group of patients. In addition there was variability for each patient between the period since having last received myelotoxic chemotherapy treatment and entry onto the study (Table I) . Thus these patients would be expected to have different hemopoietic stem cell reserves leading to the variable response to G-CSF although intrinsic individual variation might also be expected in response to G-CSF. This issue could be better addressed in patients who had not received prior chemotherapy. Despite this variation, this technique was successful in harvesting > 30 x 104 GM-CFC kg-' in eight of 21 patients.
Two alterations in the collection protocol were analysed in an attempt to optimise mobilisation and collection of PBPC. One addressed the question of leukapheresis collection schedule. It was possible that harvesting of progenitor cells on consecutive days may have contributed to the decline in PBPC levels between days 5 and 7. Therefore, progenitor cells were subsequently harvested on days 4, 6 and 8. This did not increase the number of PBPC obtained on alternate days and actually resulted in half the total number of PBPC being collected due to lower levels at day 4 and 8. A second approach involved the administration of two cycles of G-CSF. In two patients there was no difference in the ability of G-CSF to mobilise progenitor cells after one or two cycles of G-CSF.
The mechanism involved in G-CSF induced PBPC mobilisation is unknown. Several studies have failed to demonstrate an increase in progenitor cells in bone marrow in response to G-CSF (Diihrsen et al., 1988) , GM-CSF (Socinski et al., 1988; Haas et al., 1990) or Multi-CSF (IL-3) (Ottoman et al., 1990) . In addition the appearance of circulating progenitor cells of all lineages suggests a non-specific mechanism that can be triggered by general insults (such as chemotherapy) as well as by the hemopoietic regulators. However, this mechanism appears not to be totally non-specific as one of the most common subpopulations of bone marrow progenitor cells (day 7 GM-CFC) was not observed in the circulation after G-CSF treatment and furthermore, administration of IL-4 did not mobilise progenitor cells into the peripheral blood (De Luca et al., unpublished results) .
In summary, the ability to mobilise and collect PBPC using this non-toxic and efficient procedure has important implications for transplantation and high-dose chemotherapy procedures.
This work was supported in part by grants from the Anti-Cancer
Council of Victoria, the National Health and Medical Research Council, Canberra and the Victorian Health Promotion Foundation.
